The share count and the pricing of this IPO are not yet determined, but it listed the "up to"amount as $86.3 million for filing purposes.  All shares in the offering will be sold by the company rather than insiders.

The company lists J.P. Morgan Securities as the sole book-runner andalso lists Deutsche Bank Securities as co-lead manager.  Co-managersare listed as Pacific Growth Equities and Robert W. Baird & Co.

The company designs, develops, manufactures and markets a fullyintegrated molecular diagnostics system called the INFINITI™ thatautomates the discrete processes of genetic testing performed byclinical laboratories.  It already holds trademarks of INFINITI™,BioFilmChip™, Intellipac™ and Qmatic™, and it received market approvalfrom the FDA for its INFINITI™ system.

Jon C. Ogg
July 25, 2008